<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<REGINFO_RIN_DATA xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" RUN_DATE="2026-04-04-04:00" xsi:noNamespaceSchemaLocation="https://www.reginfo.gov/public/xml/REGINFO_XML_Ver10262011.xsd">
    <RIN_INFO>
        <RIN>0910-AA97</RIN>
        <PUBLICATION>
            <PUBLICATION_ID>201804</PUBLICATION_ID>
            <PUBLICATION_TITLE>Unified Agenda of Federal Regulatory and Deregulatory Actions</PUBLICATION_TITLE>
        </PUBLICATION>
        <AGENCY>
            <CODE>0910</CODE>
            <NAME>Food and Drug Administration</NAME>
            <ACRONYM>FDA</ACRONYM>
        </AGENCY>
        <PARENT_AGENCY>
            <CODE>0900</CODE>
            <NAME>Department of Health and Human Services</NAME>
            <ACRONYM>HHS</ACRONYM>
        </PARENT_AGENCY>
        <RULE_TITLE>Postmarketing Safety Reporting Requirements for Human Drug and Biological Products</RULE_TITLE>
        <ABSTRACT><![CDATA[<!DOCTYPE html>
<html>
<head>
</head>
<body>
<p>The final rule would amend the postmarketing safety reporting regulations for human drugs and biological products including blood and blood products in order to better align FDA requirements with guidelines of the International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH);&nbsp; and to update reporting requirements in light of current pharmacovigilance practice and safety information sources and enhance the quality of safety reports received by FDA. These revisions were proposed as part of a single rulemaking (68 FR 12406) to clarify and revise both premarketing and postmarketing safety reporting requirements for human drug and biological products. Premarketing safety reporting requirements were finalized in a separate final rule published on September 29, 2010 (75 FR 59961). This final rule applies to postmarketing safety reporting requirements.</p>
</body>
</html>]]></ABSTRACT>
        <PRIORITY_CATEGORY>Substantive, Nonsignificant</PRIORITY_CATEGORY>
        <RIN_STATUS>Previously Published in The Unified Agenda</RIN_STATUS>
        <RULE_STAGE>Final Rule Stage</RULE_STAGE>
        <MAJOR>No</MAJOR>
        <UNFUNDED_MANDATE_LIST>
            <UNFUNDED_MANDATE>No</UNFUNDED_MANDATE>
        </UNFUNDED_MANDATE_LIST>
        <EO_13771_DESIGNATION>Regulatory</EO_13771_DESIGNATION>
        <CFR_LIST>
            <CFR>21 CFR 310</CFR>
            <CFR>21 CFR 314</CFR>
            <CFR>21 CFR 600</CFR>
            <CFR>21 CFR 601</CFR>
            <CFR>21 CFR 606</CFR>
        </CFR_LIST>
        <LEGAL_AUTHORITY_LIST>
            <LEGAL_AUTHORITY>42 U.S.C. 216</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>42 U.S.C. 241</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>42 U.S.C. 242a</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>42 U.S.C. 262 and 263</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>42 U.S.C. 263a to 263n</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>42 U.S.C. 264</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>42 U.S.C. 300aa</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 321</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 331</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 351 to 353</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 355</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 360</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 360b to 360j</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 361a</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 371</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 374</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 375</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 379e</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 U.S.C. 381</LEGAL_AUTHORITY>
        </LEGAL_AUTHORITY_LIST>
        <LEGAL_DLINE_LIST/>
        <RPLAN_ENTRY>No</RPLAN_ENTRY>
        <TIMETABLE_LIST>
            <TIMETABLE>
                <TTBL_ACTION>NPRM</TTBL_ACTION>
                <TTBL_DATE>03/14/2003</TTBL_DATE>
                <FR_CITATION>68 FR 12406</FR_CITATION>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION>NPRM Comment Period Extended</TTBL_ACTION>
                <TTBL_DATE>06/18/2003</TTBL_DATE>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION>NPRM Comment Period End</TTBL_ACTION>
                <TTBL_DATE>07/14/2003</TTBL_DATE>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION>NPRM Comment Period Extension End</TTBL_ACTION>
                <TTBL_DATE>10/14/2003</TTBL_DATE>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION>Final Rule</TTBL_ACTION>
                <TTBL_DATE>12/00/2018</TTBL_DATE>
            </TIMETABLE>
        </TIMETABLE_LIST>
        <RFA_REQUIRED>Yes</RFA_REQUIRED>
        <SMALL_ENTITY_LIST>
            <SMALL_ENTITY>Businesses</SMALL_ENTITY>
        </SMALL_ENTITY_LIST>
        <GOVT_LEVEL_LIST>
            <GOVT_LEVEL>None</GOVT_LEVEL>
        </GOVT_LEVEL_LIST>
        <FEDERALISM>No</FEDERALISM>
        <PRINT_PAPER>Yes</PRINT_PAPER>
        <INTERNATIONAL_INTEREST>No</INTERNATIONAL_INTEREST>
        <AGENCY_CONTACT_LIST>
            <CONTACT>
                <FIRST_NAME>Jane</FIRST_NAME>
                <LAST_NAME>Baluss</LAST_NAME>
                <MIDDLE_NAME>E.</MIDDLE_NAME>
                <TITLE>Regulatory Counsel</TITLE>
                <AGENCY>
                    <CODE>0910</CODE>
                    <NAME>Food and Drug Administration</NAME>
                    <ACRONYM>FDA</ACRONYM>
                </AGENCY>
                <PHONE>301 796-3469</PHONE>
                <FAX>301 847-8440</FAX>
                <EMAIL>jane.baluss@fda.hhs.gov</EMAIL>
                <MAILING_ADDRESS>
                    <STREET_ADDRESS>Center for Drug Evaluation and Research, WO 51, Room 6278, 10903 New Hampshire Avenue,</STREET_ADDRESS>
                    <CITY>Silver Spring</CITY>
                    <STATE>MD</STATE>
                    <ZIP>20993-0002</ZIP>
                </MAILING_ADDRESS>
            </CONTACT>
        </AGENCY_CONTACT_LIST>
    </RIN_INFO>
</REGINFO_RIN_DATA>
